Jones R L, Jovanovic L, Forman S, Peterson C M
Blood. 1984 Jan;63(1):22-30.
Accelerated fibrinogen disappearance in diabetic patients is reversible with normalization of blood glucose. To define the time course of this reversal, we measured 125I-fibrinogen disappearance in 19 diabetic patients experiencing acute changes in blood glucose, as monitored and controlled by a microprocessor-controlled closed loop insulin infusion system (artificial beta cell). The data were corrected for blood volume dilutional changes and fit to a model describing two sequential exponential functions and a single exponential function. The sequential model provided the best fit for all but one patient. This indicates that there were two distinct rates of fibrinogen disappearance and suggests that the time course of reversal of accelerated fibrinogen disappearance in diabetic patients is very rapid, if not immediate. Rapid fibrinogen turnover during hyperglycemia was temporally associated with vascular volume changes, reflected as dilutional changes of 51Cr-RBC concentrations. These findings were also associated with an increase in pulse pressure during hyperglycemia, suggesting blood volume expansion due to an osmotic mechanism. The results of this study suggest a picture of vascular volume expansion and contraction, perhaps secondary to the osmotic effects of hyperglycemia. Accelerated fibrinogen turnover associated with these events may be related to increased vascular permeability and/or increased fibrin formation. These events, in concert, may contribute to the initiation and/or propagation of diabetic vascular sequelae.
糖尿病患者中纤维蛋白原清除加速现象在血糖正常化后是可逆的。为了确定这种逆转的时间进程,我们在19例血糖发生急性变化的糖尿病患者中测量了125I-纤维蛋白原的清除情况,血糖由微处理器控制的闭环胰岛素输注系统(人工β细胞)进行监测和控制。数据针对血容量稀释变化进行了校正,并拟合为一个描述两个连续指数函数和一个单一指数函数的模型。除一名患者外,连续模型对所有患者的拟合效果最佳。这表明存在两种不同的纤维蛋白原清除速率,并提示糖尿病患者中加速的纤维蛋白原清除逆转的时间进程非常迅速,即便不是即时逆转。高血糖期间纤维蛋白原周转迅速在时间上与血管容量变化相关,表现为51Cr-RBC浓度的稀释变化。这些发现还与高血糖期间脉压增加有关,提示由于渗透机制导致血容量扩张。本研究结果提示存在血管容量扩张和收缩的情况,可能继发于高血糖的渗透作用。与这些事件相关的纤维蛋白原周转加速可能与血管通透性增加和/或纤维蛋白形成增加有关。这些事件共同作用,可能促成糖尿病血管并发症的起始和/或进展。